

Peer review comments – Colchicine

Managing COVID-19 rapid guideline (NG191)

Peer review organisations

For a list of stakeholders invited to comment on COVID-19 guidance as part of the targeted peer review, please see the [targeted peer review stakeholder list](#) on the NICE website.

Overarching category	Guideline section	Theme of comments	Action taken
Hospital setting	Recommendation	No comments received	No action necessary
Hospital setting	Evidence to decision – benefits and harms	Reviewers reiterated findings from the RECOVERY study, which cannot be included in the evidence review until full results are published.	No action necessary
Hospital setting	Evidence to decision – benefits and harms	Reviewers reiterated that colchicine is associated with notable adverse events.	No action necessary
Hospital setting	Evidence to decision – certainty of the evidence	Reviewers agreed with the assessment of the certainty of the evidence.	No action necessary
Hospital setting	Evidence to decision – certainty of the evidence	Reviewers suggested that standard of care should be corticosteroids with or without tocilizumab	Corticosteroids are expected to be used more widely than tocilizumab, which has more detailed conditions for its use (see NICE's recommendation on tocilizumab for COVID-19) Therefore we retained wording that reflected the panel's discussions.
Hospital setting	Evidence to decision – acceptability	Reviewers suggested that because diarrhoea was already common in people in intensive care and increases in diarrhoea caused by colchicine may not be a major issue.	We retained the panel's view that avoiding diarrhoea would be preferable.

Hospital setting	Summary of evidence	Reviewers suggested minor wording amends for clarity	Minor wording amends for clarity
Hospital setting	Summary of evidence	Reviewers agreed with the summary of results and our confidence in the results	No action necessary
Community setting	Recommendation	Reviewers asked about aspects of clinical trial design that are outside of the remit of the guideline	No action necessary
Community setting	Evidence to decision – benefits and harms	Reviewers suggested noting there was no effect on hospital admissions.	The evidence to decision section is a summary of the panel’s discussions, which did not focus on this outcome. However, we have now added a reference to hospital admission in this section.
Community setting	Evidence to decision – benefits and harms	Reviewers asked about aspects of clinical trial design that are outside of the remit of the guideline	No action necessary
Community setting	Summary of evidence	Reviewers suggested minor wording amends for clarity	Minor wording amends for clarity